Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 2
2012 6
2013 1
2014 1
2015 1
2016 1
2017 1
2018 3
2019 3
2020 6
2021 7
2022 2
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.
Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jereczek-Fossa BA, Westhoff P, But-Hadzic J, Widder J, Geets X, Bral S, Lambrecht M, Billiet C, Sirak I, Ramella S, Giovanni Battista I, Benavente S, Zapatero A, Romero F, Zilli T, Khanfir K, Hemmatazad H, de Bari B, Klass DN, Adnan S, Peulen H, Salinas Ramos J, Strijbos M, Popat S, Ost P, Guckenberger M. Kroeze SGC, et al. Lancet Oncol. 2023 Mar;24(3):e121-e132. doi: 10.1016/S1470-2045(22)00752-5. Lancet Oncol. 2023. PMID: 36858728 Review.
Editorial: Stereotactic body radiotherapy for lung cancer.
Liu A, Kroeze SGC. Liu A, et al. Among authors: kroeze sgc. Front Oncol. 2023 Apr 28;13:1206736. doi: 10.3389/fonc.2023.1206736. eCollection 2023. Front Oncol. 2023. PMID: 37188178 Free PMC article. No abstract available.
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer.
Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, Farolfi A, Koerber SA, Debus J, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SKB, Shelan M, Aebersold DM, Grosu AL, Ceci F, Henkenberens C, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Bartenstein P, Hruby G, Scharl S, Wiegel T, Emmett L, Arnoux A, Schmidt-Hegemann NS. Zamboglou C, et al. Among authors: kroeze sgc. JAMA Netw Open. 2023 May 1;6(5):e2314748. doi: 10.1001/jamanetworkopen.2023.14748. JAMA Netw Open. 2023. PMID: 37219907 Free PMC article.
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, Giuseppe Morganti A, Trapp C, Koerber SA, Debus J, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Ruf J, Grosu AL, Ceci F, Fendler WP, Bartenstein P, Kroeze SGC, Guckenberger M, Krafcsik M, Klopscheck C, Fanti S, Hruby G, Emmett L, Belka C, Stief C, Schmidt-Hegemann NS, Henkenberens C, Mayer B, Miksch J, Shelan M, Aebersold DM, Thamm R, Wiegel T. Scharl S, et al. Among authors: kroeze sgc. Radiother Oncol. 2023 Jul;184:109678. doi: 10.1016/j.radonc.2023.109678. Epub 2023 May 3. Radiother Oncol. 2023. PMID: 37146766 Free article.
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, Debus J, Peeken JC, Vogel ME, Vrachimis A, Spohn SKB, Shelan M, Aebersold D, Grosu AL, Ceci F, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Hruby G, Scharl S, Wiegel T, Bartenstein P, Henkenberens C, Emmett L, Schmidt-Hegemann NS, Ferentinos K, Zamboglou C. Solomonidou N, et al. Among authors: kroeze sgc. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2529-2536. doi: 10.1007/s00259-023-06185-5. Epub 2023 Mar 11. Eur J Nucl Med Mol Imaging. 2023. PMID: 36905411 Free PMC article.
Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study.
Christ SM, Pohl K, Muehlematter UJ, Heesen P, Kühnis A, Willmann J, Ahmadsei M, Badra EV, Kroeze SGC, Mayinger M, Andratschke N, Huellner M, Guckenberger M. Christ SM, et al. Among authors: kroeze sgc. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):596-602. doi: 10.1016/j.ijrobp.2022.06.100. Epub 2022 Jul 28. Int J Radiat Oncol Biol Phys. 2022. PMID: 35908582
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, Lanzafame H, Trapp C, Koerber SA, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Grosu AL, Kroeze SGC, Guckenberger M, Fanti S, Hruby G, Emmett L, Belka C, Schmidt-Hegemann NS, Henkenberens C, Aebersold DM, Wiegel T, Afshar-Oromieh A, Zamboglou C, Shelan M. Adebahr S, et al. Among authors: kroeze sgc. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):558-567. doi: 10.1007/s00259-023-06438-3. Epub 2023 Sep 22. Eur J Nucl Med Mol Imaging. 2024. PMID: 37736808 Free PMC article.
Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?
Champion A, Zwhalen DR, Oehler C, Taussky D, Kroeze SGC, Burger IA, Benzaquen D. Champion A, et al. Among authors: kroeze sgc. Front Oncol. 2023 Sep 20;13:1268309. doi: 10.3389/fonc.2023.1268309. eCollection 2023. Front Oncol. 2023. PMID: 37799463 Free PMC article.
36 results